Alterations of the Immune System in Thymic Malignancies

Slides:

Advertisements

Similar presentations

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Advertisements

E13-01: Insights into thymic epithelial tumor: pathology

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

ALK FISH and IHC: You Cannot Have One without the Other

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

Brett W. Carter, MD, Edith M. Marom, MD, Frank C. Detterbeck, MD

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Frank Detterbeck, MD Journal of Thoracic Oncology

The Thymus and the Immune System: Layered Levels of Control

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Michael A. den Bakker, MD, PhD, Anja C

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors

Immunotherapy for Lung Cancer

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Heidi B. Rolke, Frode Gallefoss Journal of Thoracic Oncology

Mitotic Inhibitors Journal of Thoracic Oncology

A Translational View of the Molecular Pathogenesis of Lung Cancer

Thymoma and Thymic Carcinoma: Molecular Pathology and Targeted Therapy

Mirror Mirror on the Wall, Who Is the Fairest of Them All

The Number of Pulmonary Metastases: Influence on Practice and Outcome

MTP13-01: Indications and limitations of bronchoscopy

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Pulmonary Metastasectomy in Breast Cancer

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor Carrie.

Phase I Study of Lenalidomide in Solid Tumors

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Extended Resections for Thymic Malignancies

Genetic Changes in Squamous Cell Lung Cancer: A Review

Eystein S. Husebye, Mark S. Anderson Immunity

MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a.

International Thymic Malignancies Interest Group: A Way Forward

Eystein S. Husebye, Mark S. Anderson Immunity

European Lung Cancer Conference (ELCC) 2016 Organisation

S-1 Treatment for Chemorefractory Thymic Carcinoma

P2.03b-002 Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer Xiaorong Dong, Ruiguang Zhang, Xican.

Novel Drugs—Miscellaneous Category

IASLC 6th Latin American Conference on Lung Cancer

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

Epidemiology of Thymoma and Associated Malignancies

Who should decide margin length in pulmonary excision of lung cancer?

Induction Therapy For Locally Advanced Thymoma

Cytokine Gene Therapy for Malignant Pleural Mesothelioma

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

Presentation transcript:

Alterations of the Immune System in Thymic Malignancies Benny Weksler, MD, Binfeng Lu, PhD Journal of Thoracic Oncology Volume 9, Issue 9, Pages S137-S142 (September 2014) DOI: 10.1097/JTO.0000000000000299 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Parallel, coexisting pathways proposed to explain autoimmune disorders in patients with APECED or thymoma. Left panel, In the normal thymus, interaction between T-cells and AIRE-dependent TSAs leads to destruction of autoreactive cells (negative selection). Center panel, Defective negative selection. Failure in negative selection generates autoreactive cells that, with time, escape peripheral tolerance mechanisms (anergy induction) and engage normal tissue, causing autoimmunity. Right panel, Active autoimmunization. T-cells are immunized in the thymus (which has become a “dangerous” antigenic environment) against local antigens (e.g., skeletal muscle antigens, parathyroid tissue, cytokines, and interferons). These cells are ready for immediate attack and induction of antibody response. Reproduced with permission from Kisand et al.40 Journal of Thoracic Oncology 2014 9, S137-S142DOI: (10.1097/JTO.0000000000000299) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions